{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,1,23]],"date-time":"2026-01-23T17:35:30Z","timestamp":1769189730098,"version":"3.49.0"},"reference-count":34,"publisher":"Elsevier BV","issue":"1","license":[{"start":{"date-parts":[[2014,1,1]],"date-time":"2014-01-01T00:00:00Z","timestamp":1388534400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Joint Bone Spine"],"published-print":{"date-parts":[[2014,1]]},"DOI":"10.1016\/j.jbspin.2013.05.001","type":"journal-article","created":{"date-parts":[[2013,6,21]],"date-time":"2013-06-21T16:03:06Z","timestamp":1371830586000},"page":"69-75","source":"Crossref","is-referenced-by-count":24,"title":["Treatment persistence and changes in fracture risk, back pain, and quality of life amongst patients treated with teriparatide in routine clinical care in France: Results from the European Forsteo Observational Study"],"prefix":"10.1016","volume":"81","author":[{"given":"Gerald","family":"Rajzbaum","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Franck","family":"Grados","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"David","family":"Evans","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Soyi","family":"Liu-Leage","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Helmut","family":"Petto","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"B\u00e9atrice","family":"Augendre-Ferrante","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"key":"10.1016\/j.jbspin.2013.05.001_bib0005","doi-asserted-by":"crossref","first-page":"394","DOI":"10.1016\/j.jbspin.2008.10.008","article-title":"Prevalence and features of osteoporosis in the French general population: the Instant study","volume":"76","author":"Lespessailles","year":"2009","journal-title":"Joint Bone Spine"},{"key":"10.1016\/j.jbspin.2013.05.001_bib0010","doi-asserted-by":"crossref","first-page":"237","DOI":"10.1007\/s11657-012-0102-3","article-title":"Epidemiological burden of postmenopausal osteoporosis in France from 2010 to 2020: estimations from a disease model","volume":"7","author":"Cawston","year":"2012","journal-title":"Arch Osteoporos"},{"key":"10.1016\/j.jbspin.2013.05.001_bib0015","doi-asserted-by":"crossref","first-page":"1617","DOI":"10.1007\/s00198-007-0413-1","article-title":"Mild prevalent and incident vertebral fractures are risk factors for new fractures","volume":"18","author":"Roux","year":"2007","journal-title":"Osteoporos Int"},{"key":"10.1016\/j.jbspin.2013.05.001_bib0020","doi-asserted-by":"crossref","first-page":"895","DOI":"10.1007\/s00198-007-0530-x","article-title":"Back pain in osteoporotic vertebral fractures","volume":"19","author":"Francis","year":"2008","journal-title":"Osteoporos Int"},{"key":"10.1016\/j.jbspin.2013.05.001_bib0025","first-page":"1579","article-title":"The impact of incident vertebral and non-vertebral fragility fractures on health-related quality of life in established postmenopausal osteoporosis: results from the teriparatide randomized, placebo-controlled trial in postmenopausal women","volume":"30","author":"Oglesby","year":"2003","journal-title":"J Rheumatol"},{"key":"10.1016\/j.jbspin.2013.05.001_bib0030","doi-asserted-by":"crossref","first-page":"2175","DOI":"10.1007\/s00198-005-2023-0","article-title":"The severity of vertebral fractures and health-related quality of life in osteoporotic postmenopausal women","volume":"16","author":"Fechtenbaum","year":"2005","journal-title":"Osteoporos Int"},{"key":"10.1016\/j.jbspin.2013.05.001_bib0035","first-page":"222","article-title":"Economic burden of osteoporosis in women: data from the 2008 French hospital database (PMSI)","volume":"30","author":"Maravic","year":"2012","journal-title":"Clin Exp Rheumatol"},{"key":"10.1016\/j.jbspin.2013.05.001_bib0040","doi-asserted-by":"crossref","first-page":"304","DOI":"10.1016\/j.jbspin.2012.02.014","article-title":"2012 update of French guidelines for the pharmacological treatment of postmenopausal osteoporosis","volume":"79","author":"Briot","year":"2012","journal-title":"Joint Bone Spine"},{"key":"10.1016\/j.jbspin.2013.05.001_bib0045","doi-asserted-by":"crossref","first-page":"1434","DOI":"10.1056\/NEJM200105103441904","article-title":"Effect of parathyroid hormone (1-34) on fractures and bone mineral density in postmenopausal women with osteoporosis","volume":"10","author":"Neer","year":"2001","journal-title":"N Engl J Med"},{"key":"10.1016\/j.jbspin.2013.05.001_bib0050","unstructured":"Summary of product characteristics - Forsteo. EMA 2012 June 7 http:\/\/www.emea.europa.eu\/ema\/index.jsp?curl=pages\/medicines\/human\/medicines\/000425\/human_med_000798.jsp."},{"key":"10.1016\/j.jbspin.2013.05.001_bib0055","unstructured":"Haute autorit\u00e9 de sant\u00e9. Avis de la Commission: FORSTEO 20\u00a0microgrammes\/80\u00a0microlitres, solution pour injection en stylo pr\u00e9-rempli."},{"key":"10.1016\/j.jbspin.2013.05.001_bib0060","doi-asserted-by":"crossref","first-page":"2219","DOI":"10.1056\/NEJMp0706892","article-title":"In defense of pharmacoepidemiology\u2013embracing the yin and yang of drug research","volume":"357","author":"Avorn","year":"2007","journal-title":"N Engl J Med"},{"key":"10.1016\/j.jbspin.2013.05.001_bib0065","doi-asserted-by":"crossref","first-page":"1215","DOI":"10.1136\/bmj.312.7040.1215","article-title":"Why we need observational studies to evaluate the effectiveness of health care","volume":"11","author":"Black","year":"1996","journal-title":"BMJ"},{"key":"10.1016\/j.jbspin.2013.05.001_bib0070","doi-asserted-by":"crossref","first-page":"533","DOI":"10.1007\/s001980070097","article-title":"Study subjects and ordinary patients","volume":"11","author":"Dowd","year":"2000","journal-title":"Osteoporos Int"},{"key":"10.1016\/j.jbspin.2013.05.001_bib0075","doi-asserted-by":"crossref","first-page":"2709","DOI":"10.1007\/s00198-010-1498-5","article-title":"Fracture rate and back pain during and after discontinuation of teriparatide: 36-month data from the European Forsteo Observational Study (EFOS)","volume":"22","author":"Fahrleitner-Pammer","year":"2011","journal-title":"Osteoporos Int"},{"key":"10.1016\/j.jbspin.2013.05.001_bib0080","doi-asserted-by":"crossref","first-page":"53","DOI":"10.1016\/0168-8510(96)00822-6","article-title":"EuroQol: the current state of play","volume":"37","author":"Brooks","year":"1996","journal-title":"Health Policy"},{"key":"10.1016\/j.jbspin.2013.05.001_bib0085","doi-asserted-by":"crossref","first-page":"199","DOI":"10.1016\/0168-8510(90)90421-9","article-title":"EuroQol\u2013a new facility for the measurement of health-related quality of life. The EuroQol Group","volume":"16","author":"EuroQol Group","year":"1990","journal-title":"Health Policy"},{"key":"10.1016\/j.jbspin.2013.05.001_bib0090","doi-asserted-by":"crossref","first-page":"121","DOI":"10.2307\/2531248","article-title":"Longitudinal data analysis for discrete and continuous outcomes","volume":"42","author":"Zeger","year":"1986","journal-title":"Biometrics"},{"key":"10.1016\/j.jbspin.2013.05.001_bib0095","doi-asserted-by":"crossref","first-page":"377","DOI":"10.1185\/030079908X261087","article-title":"Characterization of patients in the European Forsteo Observational Study (EFOS): postmenopausal women entering teriparatide treatment in a community setting","volume":"24","author":"Rajzbaum","year":"2008","journal-title":"Curr Med Res Opin"},{"key":"10.1016\/j.jbspin.2013.05.001_bib0100","doi-asserted-by":"crossref","first-page":"510398","DOI":"10.4061\/2011\/510398","article-title":"Fracture incidence, quality of life, and back pain during 18-months treatment with teriparatide in Greek postmenopausal women with osteoporosis: results from the European Forsteo Observational Study","volume":"2011","author":"Aloumanis","year":"2011","journal-title":"J Osteoporos"},{"key":"10.1016\/j.jbspin.2013.05.001_bib0105","doi-asserted-by":"crossref","first-page":"484","DOI":"10.1007\/s00223-009-9299-6","article-title":"Reduction in fracture rate and back pain and increased quality of life in postmenopausal women treated with teriparatide: 18-month data from the European Forsteo Observational Study (EFOS)","volume":"85","author":"Langdahl","year":"2009","journal-title":"Calcif Tissue Int"},{"key":"10.1016\/j.jbspin.2013.05.001_bib0110","doi-asserted-by":"crossref","first-page":"2055","DOI":"10.1016\/j.clinthera.2007.09.024","volume":"29","author":"Adachi","year":"2007","journal-title":"Clin Ther"},{"key":"10.1016\/j.jbspin.2013.05.001_bib0115","doi-asserted-by":"crossref","first-page":"1626","DOI":"10.1007\/s00198-006-0171-5","article-title":"Persistence with teriparatide in patients with osteoporosis: the UK experience","volume":"17","author":"Arden","year":"2006","journal-title":"Osteoporos Int"},{"key":"10.1016\/j.jbspin.2013.05.001_bib0120","doi-asserted-by":"crossref","first-page":"625","DOI":"10.1007\/s00198-008-0698-8","article-title":"Persistence with teriparatide in postmenopausal osteoporosis; impact of a patient education and follow-up program: the French experience","volume":"20","author":"Briot","year":"2009","journal-title":"Osteoporos Int"},{"key":"10.1016\/j.jbspin.2013.05.001_bib0125","doi-asserted-by":"crossref","first-page":"735","DOI":"10.1530\/EJE-11-0959","article-title":"Persistence at 1 year of oral antiosteoporotic drugs: a prospective study in a comprehensive health insurance database","volume":"166","author":"Confavreux","year":"2012","journal-title":"Eur J Endocrinol"},{"key":"10.1016\/j.jbspin.2013.05.001_bib0130","doi-asserted-by":"crossref","first-page":"1023","DOI":"10.1007\/s00198-006-0322-8","article-title":"A systematic review of persistence and compliance with bisphosphonates for osteoporosis","volume":"18","author":"Cramer","year":"2007","journal-title":"Osteoporos Int"},{"key":"10.1016\/j.jbspin.2013.05.001_bib0135","doi-asserted-by":"crossref","first-page":"741","DOI":"10.1007\/s00198-010-1335-x","article-title":"Efficacy, side effects and route of administration are more important than frequency of dosing of anti-osteoporosis treatments in determining patient adherence: a critical review of published articles from 1970 to 2009","volume":"22","author":"Lee","year":"2011","journal-title":"Osteoporos Int"},{"key":"10.1016\/j.jbspin.2013.05.001_bib0140","doi-asserted-by":"crossref","first-page":"1103","DOI":"10.1007\/s00198-011-1843-3","article-title":"The impact of teriparatide adherence and persistence on fracture outcomes","volume":"23","author":"Yu","year":"2012","journal-title":"Osteoporos Int"},{"key":"10.1016\/j.jbspin.2013.05.001_bib0145","doi-asserted-by":"crossref","first-page":"151","DOI":"10.1186\/1472-6963-11-151","article-title":"Cost of non-persistence with oral bisphosphonates in post-menopausal osteoporosis treatment in France","volume":"11","author":"Cotte","year":"2011","journal-title":"BMC Health Serv Res"},{"key":"10.1016\/j.jbspin.2013.05.001_bib0150","doi-asserted-by":"crossref","first-page":"1507","DOI":"10.1359\/JBMR.050501","article-title":"Sustained nonvertebral fragility fracture risk reduction after discontinuation of teriparatide treatment","volume":"20","author":"Prince","year":"2005","journal-title":"J Bone Miner Res"},{"key":"10.1016\/j.jbspin.2013.05.001_bib0155","doi-asserted-by":"crossref","first-page":"2024","DOI":"10.1001\/archinte.164.18.2024","article-title":"Sustained vertebral fracture risk reduction after withdrawal of teriparatide in postmenopausal women with osteoporosis","volume":"11","author":"Lindsay","year":"2004","journal-title":"Arch Intern Med"},{"key":"10.1016\/j.jbspin.2013.05.001_bib0160","doi-asserted-by":"crossref","first-page":"1630","DOI":"10.1007\/s00198-006-0177-z","article-title":"Reduction in the risk of developing back pain persists at least 30 months after discontinuation of teriparatide treatment: a meta-analysis","volume":"17","author":"Nevitt","year":"2006","journal-title":"Osteoporos Int"},{"key":"10.1016\/j.jbspin.2013.05.001_bib0165","doi-asserted-by":"crossref","first-page":"2141","DOI":"10.1007\/s00198-011-1856-y","article-title":"The effect of teriparatide compared with risedronate on reduction of back pain in postmenopausal women with osteoporotic vertebral fractures","volume":"23","author":"Hadji","year":"2012","journal-title":"Osteoporos Int"},{"key":"10.1016\/j.jbspin.2013.05.001_bib0170","doi-asserted-by":"crossref","first-page":"2863","DOI":"10.1007\/s00198-012-1935-8","article-title":"Burden of non-hip, non-vertebral fractures on quality of life in postmenopausal women: The Global Longitudinal study of Osteoporosis in Women (GLOW)","volume":"23","author":"Roux","year":"2012","journal-title":"Osteoporos Int"}],"container-title":["Joint Bone Spine"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1297319X13001206?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1297319X13001206?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2018,10,15]],"date-time":"2018-10-15T03:28:47Z","timestamp":1539574127000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1297319X13001206"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2014,1]]},"references-count":34,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2014,1]]}},"alternative-id":["S1297319X13001206"],"URL":"https:\/\/doi.org\/10.1016\/j.jbspin.2013.05.001","relation":{},"ISSN":["1297-319X"],"issn-type":[{"value":"1297-319X","type":"print"}],"subject":[],"published":{"date-parts":[[2014,1]]}}}